Astrocyte Biomarkers in Alzheimer's Disease.

Détails

ID Serval
serval:BIB_2AEECA9C14BA
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Astrocyte Biomarkers in Alzheimer's Disease.
Périodique
Trends in molecular medicine
Auteur(s)
Carter S.F., Herholz K., Rosa-Neto P., Pellerin L., Nordberg A., Zimmer E.R.
ISSN
1471-499X (Electronic)
ISSN-L
1471-4914
Statut éditorial
Publié
Date de publication
02/2019
Peer-reviewed
Oui
Volume
25
Numéro
2
Pages
77-95
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Astrocytic contributions to Alzheimer's disease (AD) progression were, until recently, largely overlooked. Astrocytes are integral to normal brain function and astrocyte reactivity is an early feature of AD, potentially providing a promising target for preclinical diagnosis and treatment. Several in vivo AD biomarkers already exist, but presently there is a paucity of specific and sensitive in vivo astrocyte biomarkers that can accurately measure preclinical AD. Measuring monoamine oxidase-B with neuroimaging and glial fibrillary acidic protein from bodily fluids are biomarkers that are currently available. Developing novel, more specific, and sensitive astrocyte biomarkers will make it possible to pharmaceutically target chemical pathways that preserve beneficial astrocytic functions in response to AD pathology. This review discusses astrocyte biomarkers in the context of AD.
Mots-clé
Alzheimer’s disease, astrocytes, biomarkers, fluid, imaging
Pubmed
Web of science
Création de la notice
04/02/2019 11:37
Dernière modification de la notice
21/08/2019 6:35
Données d'usage